New drugs and dosage forms

October 2011
American Journal of Health-System Pharmacy;10/1/2011, Vol. 68 Issue 19, p1764
Academic Journal
The article offers information on the dosage forms of several new drugs, including brentuximab vedotin injection (marketed as Adcetris by Seattle Genetics), crizotinib capsules (marketed as Xalkori by Pfizer), and icatibant injection (marketed as Firazyr by Shire).


Related Articles

  • An Overview of Novel Therapies for Acute Hereditary Angioedema. Firszt, Rafael; Frank, Michael M. // American Journal of Clinical Dermatology;2010, Vol. 11 Issue 6, p383 

    Hereditary angioedema is an episodic swelling disorder with autosomal dominant inheritance. Attacks are characterized by nonpitting edema of external or mucosal body surfaces. Patients often present with swelling of the extremities, abdominal pain, and swelling of the mouth and throat, which can...

  • Hereditary angioedema: A clinical review for the otolaryngologist. Anon, Jack B. // ENT: Ear, Nose & Throat Journal;Jan2011, Vol. 90 Issue 1, p32 

    The article offers clinical information on hereditary angioedema (HAE), a rare genetic disorder characterized with either low levels of C1 esterase inhibitor (C1-INH) or the presence of dysfunctional C1-INH. The pathophysiology and genetic defects associated with HAE are described. Differential...

  • CASE 1 DIAGNOSIS: HEREDITARY ANGIOEDEMA. Silverman, Jason A; Yeung, Alfred K; Jain, Sangeeta; Kavadas, Fotini D // Paediatrics & Child Health (1205-7088);May2014, Vol. 19 Issue 5, p234 

    The article presents a case study of a person diagnosed with hereditary angioedema (HAE). The patient's abdominal pain improved a lot within 24 hours. Complement assays showed normal C3, low normal C4, and low Cl esterase inhibitor functional activity. HAE is a multisystem disease which features...

  • Diagnosis and treatment of hereditary angio-oedema attacks. Longhurst, Hilary J.; Nzeako, Ugo C. // British Journal of Hospital Medicine (17508460);Mar2012, Vol. 73 Issue 3, p148 

    Patients with hereditary angio-oedema will often present to the emergency department or hospital with cutaneous swelling, abdominal pain or laryngeal oedema. This article reviews the diagnosis and acute management of patients with hereditary angio-oedema.

  • New drugs and dosage forms.  // American Journal of Health-System Pharmacy;1/15/2012, Vol. 69 Issue 2, p90 

    The article offers information on the dosage forms of the new drugs oxybutynin gel (Anturol by Antares Pharma) for treatment of overactive bladder with symptoms of urge urinary incontinence; and extended release oxymorphone hydrochloride tablets (Opana ER by Endo Pharmaceuticals).

  • Clinical Management of Hereditary Angioedema. Weitzel, Rhonda // International Student Journal of Nurse Anesthesia;Summer2013, Vol. 12 Issue 2, p28 

    The article presents a case study of a 57-year-old Caucasian male who underwent an outpatient colonoscopy and drainage of rectal abscess. It states that the anesthesia assessment was performed with a special focus on the patient's history of hereditary angioedema, an autosomal dominant disorder...

  • Epidermal Growth Factor Receptor Mutations and Radiotherapy in Non-small Cell Lung Cancer. ZHONG, Xing; WANG, Jin // Chinese Journal of Lung Cancer;Mar2013, Vol. 16 Issue 3, p157 

    Radiotherapy plays a pivotal role in the treatment for lung cancer. Epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC) which predicts tyrosine kinase inhibitor (TKI) treatment response may also has effect on radiation response. NSCLC harboring kinase-domain...

  • Why technical aspects rather than biology explain cellular heterogeneity in ALK-positive non-small cell lung cancer. Mcleer-Florin, Anne; LantuĂ©joul, Sylvie // Journal of Thoracic Disease;Jun2012, Vol. 4 Issue 3, p240 

    The authors offer information on anaplastic lymphoma kinase (ALK) gene rearrangements leading to non small cell lung cancers (NSCLC) such as adenocarcinomas. They discuss a study by Camidge and colleagues, which correlates the percentage of ALK+ cells and signal copy number as assessed by...

  • Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer... Kelley, Michael J.; Nakagawa, Kazuhiko // JNCI: Journal of the National Cancer Institute;5/17/95, Vol. 87 Issue 10, p756 

    Explores the association between human cyclin-dependent kinase 4 inhibitor (CDKN2) gene loss and the clinical status of lung cancer patients. Isolation of the DNA from the tumor cell line; Analysis of the CDKN2 gene by agarose gel electrophoresis and DNA blotting; Evaluation of the CDKN2 gene...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics